Spondyloarthritis & psoriatic arthritis
Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients With Psoriatic Arthritis
Authors' conclusion
Secondary failure to bDMARD is common in PsA and may be influenced by both disease- and therapy-related factors.
Study context
- Population
- Patients with psoriatic arthritis (PsA) who initiated and remained on biologic disease-modifying antirheumatic drugs (bDMARDs) for ≥ 1 year after clinic enrollment, 2000–2023264 responders at 1 year
- Participants
- 482 patients
- Outcome
- Secondary failure to bDMARD (inability to maintain response criteria or clinician's judgment of loss of effectiveness) among 1-year responders
Methodological detailssingle-centre, specialized-care, observational, Cox regression
- Single-centre
- Specialized-care
- Observational
- Cox regression
Main finding
As reported in the abstract
Secondary failure among 1-year responders
Responders at 1 year
264
54.8%
Responders developing secondary failure
94
35.6%
Median time to secondary failure from response, years (IQR 0.7-3.8)
1.6
Observational data: associations, not effects.
Further findings
Factors associated with secondary failure (multivariable Cox model)
| HR (95% CI) | ||
|---|---|---|
| Higher SJC at baseline | 1.39 (1.05–1.84) | |
| Higher PASI at baseline | 1.14 (1.01–1.29) | |
| First-line bDMARD initiation | 0.48 (0.25–0.91) | |
| Initiation in more recent calendar years | 0.34 (0.12–0.98) | |
| 0.10.31310Hazard ratio (log scale) |
| Outcome | HR (95% CI) | |
|---|---|---|
| Factors associated with secondary failure (multivariable Cox model)TNFivs Other bDMARD | 0.39 (0.18–0.88) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients With Psoriatic Arthritis. J Rheumatol. Published 1 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →